Perinatal mood disorders are a tremendous burden to childbearing families and treatment with selective serotonin reuptake inhibitor (SSRI) antidepressants is increasingly common. Exposure to SSRIs may affect serotonin signaling and ultimately, microbes that live in the gut. Health of the gut microbiome during pregnancy, lactation, and early infancy is critical, yet there is limited evidence to describe the relationship between SSRI exposure and gut microbiome status in this population. The purpose of this Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)-compliant scoping review is to assess evidence and describe key concepts regarding whether SSRI exposure affects the maternal and infant gut microbiome. Sources were collected from PubMed, Web of Science, and Scopus databases, and an additional gray literature search was performed. Our search criteria returned only three sources, two rodent models and one human subjects research study. Results suggest that fluoxetine (SSRI) exposure may affect maternal gut microbiome dynamics during pregnancy and lactation. There were no available sources to describe the relationship between perinatal SSRI exposure and the infant gut microbiome. There is a significant gap in the literature regarding whether SSRI antidepressants affect the maternal and infant gut microbiome. Future studies are required to better understand how SSRI antidepressant exposure affects perinatal health.

中文翻译：

---

怀孕和哺乳期间的选择性血清素再摄取抑制剂：对母婴肠道微生物组影响的范围审查

围产期情绪障碍对育龄家庭来说是一个巨大的负担，选择性血清素再摄取抑制剂（SSRI）抗抑郁药的治疗越来越普遍。接触 SSRI 可能会影响血清素信号传导，并最终影响肠道内的微生物。妊娠期、哺乳期和婴儿早期肠道微生物组的健康至关重要，但描述 SSRI 暴露与该人群肠道微生物组状态之间关系的证据有限。本系统评价和荟萃分析首选报告项目 (PRISMA) 合规范围界定审查的目的是评估证据并描述有关 SSRI 暴露是否影响母婴肠道微生物组的关键概念。来源是从 PubMed、Web of Science 和 Scopus 数据库收集的，并进行了额外的灰色文献检索。我们的搜索标准仅返回三个来源，两个啮齿动物模型和一项人类受试者研究。结果表明，氟西汀（SSRI）暴露可能会影响怀孕和哺乳期间母体肠道微生物群的动态。没有可用的来源来描述围产期 SSRI 暴露与婴儿肠道微生物群之间的关系。关于 SSRI 抗抑郁药是否影响母婴肠道微生物组，文献中存在显着差距。未来的研究需要更好地了解 SSRI 抗抑郁药物暴露如何影响围产期健康。